NOTIFICATION OF TRANSACTIONS OF DIRECTORS

VERNALIS PLC (the "Company")

14 October 2014

Vernalis plc (LSE: VER) announces it has, today, been informed that, on 13 October 2014, the following director bought shares in the Company:

·    Nigel Sheail, Non-Executive Director, purchased a total of 103,000 Ordinary shares of 1 pence each at an average price of 48.7 pence per share.  Mr Sheail is now the beneficial holder of 210,000 Ordinary 1 pence shares, representing 0.047% of the Company's current issued share capital.

Enquiries :

Vernalis plc:


Ian Garland, Chief Executive Officer

+44 (0) 118 938 0015

David Mackney, Chief Financial Officer


Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8350

Lucy Tilley


Dr Julian Feneley


Henry Fitzgerald-O'Connor


Shore Capital (Joint Broker):

+44 (0)20 7408 4090

Bidhi Bhoma


Toby Gibbs


Brunswick Group:

+44 (0) 20 7404 5959

Jon Coles


Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development.  The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline.  Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies.  The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visitwww.vernalis.com


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSKMMMGDDDGDZM
distributed by